Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06249152 · ClinicalTrials.gov registry record · Phase 2
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
A Phase 2 study, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT06249152 is a Phase 2 study that has completed, run by Qlaris Bio. The registered enrollment target is 36 participants.
The verdict
NCT06249152, a Phase 2 study, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
Interventions
- DRUG QLS-111, 0.015%
- DRUG QLS-111, 0.030%
- DRUG QLS-111, 0.075%
- DRUG QLS-111 vehicle ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-04-21 |
| Est. Completion | 2024-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06249152
The ClinicalTrials.gov registry entry for NCT06249152 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qlaris Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which QLS-111, 0.015% is the first listed.
NCT06249152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06249152 about?
NCT06249152 is a clinical study titled "Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients". Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
What is the current status of trial NCT06249152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-04-21. Estimated completion is 2024-12-20.
What interventions are being tested in trial NCT06249152?
The interventions under investigation include: QLS-111, 0.015% (DRUG), QLS-111, 0.030% (DRUG), QLS-111, 0.075% (DRUG), QLS-111 vehicle ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT06249152?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.